PT  - JOURNAL ARTICLE
AU  - Martinez-Acuña, Natalia
AU  - Avalos-Nolazco, Diana
AU  - Rodriguez-Rodriguez, Diana
AU  - Martinez-Liu, Cynthia
AU  - Taméz, Rogelio Cazares
AU  - Flores-Arechiga, Amador
AU  - Perez-Chavez, Fernando
AU  - Ayala-de-la-Cruz, Sergio
AU  - Cienfuegos-Pecina, Eduardo
AU  - Diaz-Chuc, Erik
AU  - Arellanos-Soto, Daniel
AU  - Padilla-Rivas, Gerardo
AU  - Ramos-Jimenez, Javier
AU  - Galan-Huerta, Kame
AU  - Lozano-Sepulveda, Sonia
AU  - Garza-González, Elvira
AU  - Treviño-Garza, Consuelo
AU  - Montes-de-Oca-Luna, Roberto
AU  - Lee, Aurora Beatriz
AU  - de-la-O-Cavazos, Manuel
AU  - Rivas-Estilla, Ana Maria
TI  - Seroprevalence of anti-SARS-COV-2 antibodies in blood donors from Nuevo Leon state, Mexico, during the beginning of the COVID-19 pandemic
AID  - 10.1101/2020.11.28.20240325
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.11.28.20240325
4099  - http://medrxiv.org/content/early/2020/11/30/2020.11.28.20240325.short
4100  - http://medrxiv.org/content/early/2020/11/30/2020.11.28.20240325.full
AB  - Background The progression and distribution of SARS-CoV-2 is unknown because typically only symptomatic individuals are diagnosed.Aim We evaluated the seroprevalence of anti-SARS-CoV-2 in blood donors in Nuevo Leon, Mexico as a strategy for asymptomatic case detection of COVID-19 and epidemic progression.Methods/Materials We tested 1968 blood donors that attended two regional donation centers in Northeast Mexico from January 1st to August 30, 2020, to identify anti-SARS-CoV-2 IgG by chemiluminescent immunoassay. Additionally, routine tests for donors including Brucella, Chagas, HCV, VDRL, HIV-1, and HBsAg identification were performed.Results We found 77 donors reactive for anti-SARS-CoV-2 IgG (seroprevalence 3.99%) and none of them had reported recent COVID-19 symptoms. Donors aged 18 to 49 years (89.5%) were more likely to be seropositive compared to those aged 50 years or older (10.5%) (P<0.001). Prevalence of antibodies increased each epidemiological (EPI) week, parallel to the report of confirmed cases by RT-PCR, identifying the highest prevalence between EPI week 33 and 35 (10.2% to 19%). The metropolitan area of Monterrey recorded the highest number of cases. Routine tests showed that the prevalence of anti-Brucella was 0.13%, anti-HCV 0.5%, anti-HIV-1-2 0.14%, HBsAg 0.16%, Chagas 0.48% and syphilis 1.06%.Conclusions There is a growing trend of seroprevalence over time, parallel to the constantly increasing epidemic curve in our region and it was higher under 49 years of age associated with asymptomatic infection in donors from the Nuevo Leon area. Detection of anti-SARS-CoV-2 in blood donors is a potential tool for tracking the progression and identifying population exposure during the SARS-CoV-2 outbreak.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by CONACYT Mexico Grants: 0312135 to NMA; 314867 to AMRE and 312368 to SALS.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We used exclusively residual plasma or serum from routine laboratory diagnosis of blood donors; therefore, the need for informed consent was waived. The donation of each participant was made under National and International Blood Establishment Authorization. Institution of registration: University Hospital and School of Medicine, Universidad Autonoma de Nuevo Leon.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred in this manuscript are available